Rohil Dhaliwal

This paper develops a small molecule, BRD8833, that induces BCR-ABL phosphorylation to disrupt its active site electric field, leading to loss of hyperactivity and apoptosis in BCR-ABL-dependent cancer cells.

This paper introduces GRIPs, a scalable platform for PTM editing using chimeric molecules, demonstrating functionality in multiple systems and confirming specificity through proteomics.

This study shows induced-proximity inhibitors have orthogonal resistance mechanisms to classical inhibitors, using KRAS as a model system.